Free Physician Assistant CME | CMEList.com

 


Advances in Nursing Care for Pediatric Patients with High-Risk Neuroblastoma Free Pediatric Neuroblastoma CME
Live online August 4, 2017 and September 29, 2017 and available on demand until September 29, 2018.
Posted by...Bernard Sklar, MD.
Free Oncology CME Credit hours..2.0.
CME Credits Awarded by....Postgraduate Institute for Medicine.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for pediatric oncology nurses, pediatric nurses, oncology nurses, nurse practitioners, nurse managers, infusion nurses, research nurses, physician assistants, and other health care providers who care for or have an interest in pediatric patients with high-risk neuroblastoma.
Educational material updated...September 29, 2017.
Expiration of CME credit...September 29, 2018.
Financial Support...United Therapeutics Corporation.
Advances in Nursing Care for Pediatric Patients with High-Risk Neuroblastoma consists of two presentations with discussion: Optimal Nursing Strategies to Manage Pediatric Patients with High-Risk Neuroblastoma and Recurrent/Refractory Disease of Pediatric Neuroblastoma: Enhancing the Role of the Nurse.
At the conclusion of Advances in Nursing Care for Pediatric Patients with High-Risk Neuroblastoma, you will be able to:
• Review the fundamentals of diagnosing, treating, and managing high-risk pediatric neuroblastoma
• Examine strategies to improve supportive care for children with high-risk neuroblastoma
• Examine the aspects of parental decision-making regarding appropriate care for children with recurrent/refractory neuroblastoma
• Plan strategies to improve the dialogue and working relationship with parents/caregivers of pediatric patients regarding the goals of care through the treatment continuum and beyond
Nursing Educational Objective:
After completing Advances in Nursing Care for Pediatric Patients with High-Risk Neuroblastoma, you should be able to:
• Provide appropriate care and counsel for patients and their families

Carcinoid Syndrome: Updates in Pathophysiology, Diagnosis, and Treatment Free Diabetes CME
Posted by...Bernard Sklar, MD.
Free Gastroenterology CME Credit Hours...1.0.
CME Credits Awarded by....ScientiaCME.
Cost...........Free.
Instruction Type...Slide-Video Lectures.
Target Audience...Gastroenterologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in gastroenterology; and any other healthcare professionals with an interest in or who clinically encounter patients with chronic idiopathic constipation.
Educational material updated...October 02, 2017.
Expiration of CME credit...October 02, 2019.
Financial Support...Synergy Pharmaceuticals.
Chronic Idiopathic Constipation (CIC) discusses conventional therapies: bulking agents, softeners, stimulants, osmotics; recent additions and investigational agents: prucalopride, plecanatide, linaclotide, lubiprostone; non-pharmacologic therapies and their place relative to pharmacotherapy: dietary, mechanical, behavioral, and surgical interventions; biofeedback; and clinical pearls and difficult-to-treat cases.
After reviewing Chronic Idiopathic Constipation (CIC), you will be able to:
• Describe the pathophysiology of chronic idiopathic constipation
• Describe the benefits and risks of pharmacotherapy for chronic idiopathic constipation and take them into account when formulating a treatment plan for different patients
• Formulate an evidence-based treatment plan for a variety of patients with chronic idiopathic constipation.
• Recommend therapy changes in patients with chronic idiopathic constipation who do not respond to a previously prescribed treatment
In order to receive credit from ScientiaCME, you must first establish a username and password.

The Best of Stroke Forum 2016  Free Stroke CME
Posted by...Bernard Sklar, MD. 
Free CME Credit Hours...0.5.
CME Credits Awarded by...Vindico Medical Education.
Cost for Credit...Free.
Instruction Type...Video Lectures.
Target Audience...Emergency medicine physicians, neurologists, emergency medicine residents, nurses, physician assistants, nurse practitioners, and other health care professionals involved in the treatment of patients with AIS.
Educational material last updated...November 10, 2016.
CME Credit Expires...November 9, 2017.
Financial Support...Genentech, Inc.
The Best of Stroke Forum 2016 consists of two brief lectures:
• Eligibility for IV Thrombolysis: A Review of Inclusion and Exclusion Criteria
• Stroke Therapy: Examining New Evidence
After competing The Best of Stroke Forum 2016, you should be better able to:
• Apply evidence-based criteria to the selection of candidates for thrombolytic therapy in AIS.
• Evaluate FDA labeling, current data, and clinical practice guidelines on the use of tissue plasminogen activator in the extended 3-hour to 4.5-hour post-onset window.
• Assess recent studies and guidelines on endovascular procedures for AIS.
• Determine the criteria for the concomitant or preferential use of tissue plasminogen activator in patients with AIS who are being considered for endovascular procedures.
• Incorporate shared decision making with patients and their families to improve education and assist in reducing delays in treatment and complications.

An Update on Fixed-Dose LAMA/LABA Inhalers in COPD
Posted by...Bernard Sklar, MD. Free Lung Cancer CME
Free Pulmonology CME Credit hours...2.0.
CME Credits Awarded by....The France Foundation
Cost...........Free.
Instruction Type...Text-and-Graphics.
Target Audiences...This program is intended for health care professionals who treat and manage patients with COPD.
Educational material updated....September 30, 2016.
Expiration of CME credit...September 29, 2017.
Financial Support...Boehringer Ingelheim Pharmaceuticals, Inc.
An Update on Fixed-Dose LAMA/LABA Inhalers in COPD consists of written presentations by 4 experts on the use of Fixed-Dose Inhalers in COPD
Upon completion of An Update on Fixed-Dose LAMA/LABA Inhalers in COPD, you should be able to:
• Evaluate key efficacy data from clinical trials on new and emerging fixed-dose LAMA/LABA inhalers in COPD.
• Evaluate key safety data from clinical trials on new and emerging fixed-dose LAMA/LABA inhalers in COPD.
• Apply information on the efficacy and safety of new/emerging LAMA/LABA inhalers in COPD to specific clinical scenarios.

Improving Bone Strength and Reducing Fracture Risk in Osteoporosis
Posted by...Bernard Sklar, MD. Osteoporosis CME
Free CME Credit Hours...0.5.
CME Credits Awarded by...Vindico Medical Education.
Cost for Credit...Free.
Instruction Type...Video Lectures.
Target Audience...Endocrinologists, internal medicine physicians, and other health care professionals involved in the treatment of patients with osteoporosis.
Educational material last updated...September 1, 2016.
CME Credit Expires...August 31, 2017.
Financial Support...Merck & Co., Inc.
Improving Bone Strength and Reducing Fracture Risk in Osteoporosis consists of two brief video lectures on the causes and treatments of osteoporosis.
Upon successful completion of Improving Bone Strength and Reducing Fracture Risk in Osteoporosis, you should be better able to:
• Outline the mechanisms of action of currently available and emerging resorption inhibitors, anabolic agents, and other therapeutic options for osteoporosis.
• Assess screening and diagnostic modalities that allow for the prompt management of osteoporosis.

How Low Can You Go? LDL - Is Lower Really Better?
Posted by...Bernard Sklar, MD. cholesterol CME
Free CME Credit Hours...1.0.
CME Credits Awarded by...Vindico Medical Education.
Cost for Credit...Free.
Instruction Type...Video Lectures.
Target Audience...Cardiologists, endocrinologists, primary care physicians, family physicians, internists, and other health care professionals involved in the treatment of patients with dyslipidemia.
Educational material last updated...August 25, 2016.
CME Credit Expires...August 24, 2017.
Financial Support...Amgen.
How Low Can You Go? LDL - Is Lower Really Better?  features interviews with clinical experts, who discuss newly released evidence and guidelines regarding cardiovascular risk assessment, best practices when evaluating patients with elevated LDL-C, clinical study data pertaining to the effects of lowering LDL-C beyond evidence-based recommendations, and use of non-statin therapies for the treatment of dyslipidemia in patients who cannot achieve desired target levels.
Upon successful completion of How Low Can You Go? LDL - Is Lower Really Better?, you should be better able to:
• Incorporate cardiovascular risk assessment, evidence-based guidelines, and best practices when evaluating patients with elevated LDL-C.
• Assess clinical study data pertaining to the effect of lowering LDL-C beyond evidence-based recommendations and its effect on cardiovascular risk reduction.
• Evaluate the use of non-statin therapies for the treatment of dyslipidemia in patients who are intolerant or in patients who cannot achieve desired target levels. • Incorporate therapeutic regimens with demonstrated ability to reduce risk markers other than LDL-C.
• Incorporate therapeutic regimens with demonstrated ability to reduce risk markers other than LDL-C.

Alzheimer Disease (AD) and Its Complications: Best Practices, Emerging Therapies, and Barriers to Care Alzheimer's Disease CME 
Posted by...Bernard Sklar, MD.
Alzheimer's Disease CME Credit hours...1.0.
CME Credits Awarded by....ScientiaCME.
Cost...........Free.
Instruction Type...Streaming Video Lecture.
Target Audiences...Healthcare professionals specializing in: neurology, gerontology, internal medicine, palliative care, or those who otherwise commonly care for patients with AD or who frequently encounter them or their caregivers in practice.
Educational material updated...December 21, 2015.
Expiration of CME credit...December 21, 2017.
Financial Support...AVANIR.
Topics covered in Alzheimer Disease (AD) and Its Complications include:
Epidemiology of and risk factors for Alzheimer Disease (AD), Symptomatology and diagnosis of AD, Treatment in patients with AD, Complications and barriers to optimal care in patients with AD and many more.
After completing Alzheimer Disease (AD) and Its Complications, you will be able to:
• Describe what is presently known about the pathophysiology of AD and the challenges associated with diagnosis and treatment of AD.
• Evaluate a treatment plan for a specific patient based on degree of AD to optimize safety and efficacy, suggesting modifications for improvement.
• Identify the present treatment options currently available for management of AD and apply them to patient cases using evidence-based medicine.
• Describe emerging drug therapies in the treatment of AD.
• Describe barriers to care and suggest therapies for treating cognitive and behavioral complications secondary to AD 
In order to get credit from ScientiaCME, you must first establish a username and password.